During this proposed clinical trial, the investigators intend to evaluate the pharmacodynamic anti-inflammatory properties and safety of TPI ASM8, by investigating the effect on sputum eosinophils and the airway responses during an allergen challenge at different dose levels.

The early and late asthmatic response were both significantly attenuated by the highest dose of ASM8. The methacholine challenge and other parameters (ECP, mRNA knockdown on CCR3 and B-Chain of IL-3-Il-5 and GMCSF were attenuated by ASM8.

Inclusion Criteria:

• Men and women 18 to 65 years of age
• Generally good health; steroid naïve (or who have not taken inhaled/oral corticosteroid within last month) mild to moderate, stable, allergic asthma as defined by ATS criteria
• History of episodic wheeze and shortness of breath
• Forced expiratory volume in one second (FEV1) at baseline ≥ 70% of the predicted value
• Able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.

Exclusion Criteria:

• Significant acute or chronic medical or psychiatric illness
• Known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks
• Use of inhaled or oral corticosteroids within the last 30 days, or need for antihistamines within 72 hours of each allergen or methacholine challenge, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting β2-agonist are allowed).